Xeris Pharmaceuticals Inc. [NASDAQ: XERS] gained 0.91% or 0.03 points to close at $3.33 with a heavy trading volume of 3221610 shares. The company report on May 25, 2021 that SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Strongbridge Biopharma plc Merger.
Rigrodsky Law, P.A. announces that it is investigating Strongbridge Biopharma plc (“Strongbridge”) (NASDAQ GS: SBBP) regarding possible breaches of fiduciary duties and other violations of law related to Strongbridge’s agreement to be acquired by Xeris Pharmaceuticals, Inc. (“Xeris”) (NASDAQ GS: XERS). Under the terms of the agreement, Strongbridge’s shareholders will receive 0.7840 shares of Xeris Biopharma Holdings, Inc. plus one contingent value right per share.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-strongbridge-biopharma-plc.
It opened the trading session at $3.32, the shares rose to $3.3876 and dropped to $3.23, the range by which the price of stock traded the whole day. The daily chart for XERS points out that the company has recorded -25.67% loss over the past six months. However, it is still -35.92% lower than its most recent low trading price.
If we look at the average trading volume of 2.43M shares, XERS reached to a volume of 3221610 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Xeris Pharmaceuticals Inc. [XERS]:
RBC Capital Mkts have made an estimate for Xeris Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on February 18, 2020, representing the official price target for Xeris Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $24, while RBC Capital Mkts analysts kept a Outperform rating on XERS stock.
The Average True Range (ATR) for Xeris Pharmaceuticals Inc. is set at 0.25, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 8.32. The Price to Book ratio for the last quarter was 4.62, with the Price to Cash per share for the same quarter was set at 2.03.
Trading performance analysis for XERS stock
Xeris Pharmaceuticals Inc. [XERS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.58. With this latest performance, XERS shares dropped by -13.51% in over the last four-week period, additionally sinking by -25.67% over the last 6 months – not to mention a drop of -38.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 39.85, with the RSI for the last a single of trading hit 40.48, and the three-weeks RSI is set at 39.74 for Xeris Pharmaceuticals Inc. [XERS]. The present Moving Average for the last 50 days of trading for this stock 3.88, while it was recorded at 3.37 for the last single week of trading, and 4.85 for the last 200 days.
Xeris Pharmaceuticals Inc. [XERS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Xeris Pharmaceuticals Inc. [XERS] shares currently have an operating margin of -400.52 and a Gross Margin at +54.84. Xeris Pharmaceuticals Inc.’s Net Margin is presently recorded at -446.00.
Return on Total Capital for XERS is now -84.59, given the latest momentum, and Return on Invested Capital for the company is -94.19. Return on Equity for this stock declined to -378.20, with Return on Assets sitting at -67.98. When it comes to the capital structure of this company, Xeris Pharmaceuticals Inc. [XERS] has a Total Debt to Total Equity ratio set at 257.76. Additionally, XERS Total Debt to Total Capital is recorded at 72.05, with Total Debt to Total Assets ending up at 54.68. Long-Term Debt to Equity for the company is recorded at 257.76, with the Long-Term Debt to Total Capital now at 72.05.
Reflecting on the efficiency of the workforce at the company, Xeris Pharmaceuticals Inc. [XERS] managed to generate an average of -$506,333 per employee. Receivables Turnover for the company is 3.27 with a Total Asset Turnover recorded at a value of 0.15.Xeris Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.90.
Xeris Pharmaceuticals Inc. [XERS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Xeris Pharmaceuticals Inc. posted -0.63/share EPS, while the average EPS was predicted by analysts to be reported at -0.73/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XERS.
An analysis of insider ownership at Xeris Pharmaceuticals Inc. [XERS]
There are presently around $111 million, or 52.10% of XERS stock, in the hands of institutional investors. The top three institutional holders of XERS stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 6,553,398, which is approximately New of the company’s market cap and around 2.90% of the total institutional ownership; BLACKROCK INC., holding 3,764,948 shares of the stock with an approximate value of $12.54 million in XERS stocks shares; and SESSA CAPITAL IM, L.P., currently with $11.38 million in XERS stock with ownership of nearly -18.077% of the company’s market capitalization.
Positions in Xeris Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 58 institutional holders increased their position in Xeris Pharmaceuticals Inc. [NASDAQ:XERS] by around 10,341,831 shares. Additionally, 39 investors decreased positions by around 2,825,849 shares, while 20 investors held positions by with 20,024,151 shares. The mentioned changes placed institutional holdings at 33,191,831 shares, according to the latest SEC report filing. XERS stock had 19 new institutional investments in for a total of 7,495,670 shares, while 14 institutional investors sold positions of 722,062 shares during the same period.